Biomea Fusion (BMEA) Stock Forecast & Price Target

$7.41 +0.32 (+4.51%)

(As of 12:45 PM ET)

Biomea Fusion - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
2

Buy
10

Based on 12 Wall Street analysts who have issued ratings for Biomea Fusion in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 2 have given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for BMEA.

Consensus Price Target

$30.50
311.61% Upside

According to the 12 analysts' twelve-month price targets for Biomea Fusion, the average price target is $30.50. The highest price target for BMEA is $60.00, while the lowest price target for BMEA is $11.00. The average price target represents a forecasted upside of 311.61% from the current price of $7.41.

BMEA Analyst Ratings Over Time

Type	Current Forecast 11/15/23 to 11/14/24	1 Month Ago 10/16/23 to 10/15/24	3 Months Ago 8/17/23 to 8/16/24	1 Year Ago 11/15/22 to 11/15/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$30.50	$29.40	$28.25	$43.88
Forecasted Upside	311.61% Upside	168.00% Upside	388.75% Upside	371.27% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

“This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!

BMEA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMEA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biomea Fusion Stock vs. The Competition

Type	Biomea Fusion	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	329.88% Upside	25,287.72% Upside	8.04% Upside
News Sentiment Rating	Positive News See Recent BMEA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/31/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$10.00 ➝ $19.00	+96.28%
10/31/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00	+286.85%
10/30/2024	Barclays 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$9.00 ➝ $11.00	-4.84%
10/9/2024	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/27/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Outperform ➝ Sector Outperform	$21.00 ➝ $41.00	+307.15%
9/27/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$54.00 ➝ $54.00	+464.26%
Why buying gold might be a mistake (Ad) Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up.
9/26/2024	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/26/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$18.00	+94.38%
8/29/2024	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Quibria Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00	+231.56%
8/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$45.00 ➝ $22.00	+182.05%
5/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$70.00 ➝ $60.00	+442.01%
5/3/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$14.00 ➝ $15.00	+21.95%
6/26/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
3/24/2023	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$22.00	+39.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:07 PM ET.

BMEA Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Biomea Fusion is $30.50, with a high forecast of $60.00 and a low forecast of $11.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BMEA shares.
: According to analysts, Biomea Fusion's stock has a predicted upside of 311.61% based on their 12-month stock forecasts.
: Over the previous 90 days, Biomea Fusion's stock had 4 upgrades by analysts.
: Biomea Fusion has been rated by research analysts at Barclays, Capital One Financial, Citigroup, EF Hutton Acquisition Co. I, HC Wainwright, Piper Sandler, Rodman & Renshaw, RODMAN&RENSHAW, Scotiabank, and Truist Financial in the past 90 days.
: Analysts like Biomea Fusion more than other "medical" companies. The consensus rating for Biomea Fusion is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMEA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

This page (NASDAQ:BMEA) was last updated on 11/14/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Stock Forecast & Price Target